MECHANICAL HEART VALVES
Unique design features have established Abbott mechanical heart valves—including the Regent™ and Masters Series—as a gold standard for reliability and performance, while maintaining low complication rates over the long term.
MECHANICAL HEART VALVES CLINICAL DATA
Unique design features have established Abbott mechanical heart valves—including the Regent™ and Masters Series—as a gold standard for reliability and performance, while maintaining low complication rates over the long term.
DEMONSTRATED SAFETY OVER NOTABLY LONG-TERM STUDIES
Abbott mechanical heart valves deliver exceptional hemodynamics and performance while maintaining low complication rates over the long term. The Abbott mechanical heart valves have demonstrated low late mortality and a low incidence of valve-related events over a period of at least 30 years.1,2
Saito1
Aortic Valve Replacement | Mitral Valve Replacement | |
---|---|---|
Retrospective Study | 950 patients, 30 years | 1,255 patients, 30 years |
Thromboembolism | 0.56%/pt-year | 0.99%/pt-year |
Thrombosis | 0.02%/pt-year | 0.03%/pt-year |
Bleeding Event | 0.27%/pt-year | 0.43%/pt-year |
Johnson2
Aortic Valve Replacement | Mitral Valve Replacement | |
---|---|---|
Retrospective Study | 584 patients, 30 years | 439 patients, 30 years |
Thromboembolism | 1.7%/pt-year | 2.9%/pt-year |
Thrombosis* | 0.2%/pt-year | 0.1%/pt-year |
Bleeding Event | 2.4%/pt-year | 2.0%/pt-year |
*Calculated values.
AORTIC ANTICOAGULATION MANAGEMENT
A demonstrated worldwide history of excellence over a wide INR range
Click to read the abstracts
*44/197 patients in the Lowering-IT study were implanted with Abbott Valves.
†This was further stratified into a control group, a very low INR (monitored 1x weekly), and a very low INR (monitored 2x weekly) group.
§Thromboembolic events for VL1 and VL2 groups are listed together, respectively.
¶Bleeding events for VL1 and VL2 groups are listed together, respectively.
MAT-2202033 v1.0 | Item approved for Global OUS use.